The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Benzer Materyaller

• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  Yazar:: Tseng, Jeng-Sen, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
  Yazar:: Su, Kang-Yi, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
  Yazar:: Huang, Yen-Hsiang, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients
  Yazar:: Huang, Yen-Hsiang, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
  Yazar:: Tseng, Jeng-Sen, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)